Skip to content

A multicenter, randomized controlled, open-label clinical study on the efficacy of total flavonoids of Desmodium styracifolium in the postoperative surgery of upper urinary tract stones

A multicenter, randomized controlled, open-label clinical study on the efficacy of total flavonoids of Desmodium styracifolium in the postoperative surgery of upper urinary tract stones

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094080
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-12-30
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper urinary tract stones

Interventions

Experimental group:After the operation of upper urinary tract stones, oral administration of total flavonoids of Desmodium styracifolium
Control group:No medical intervention is used after upper urinary tract stones

Sponsors

Mianzhu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18~70 years old (2) Single or multiple upper urinary tract stones, with a maximum diameter of <=2.0cm, transureteral surgery; (3) Patients with upper urinary tract stones with damp heat accumulation type in the dialectical conformity of traditional Chinese medicine; (4) Good renal function (serum creatinine <133umol/L), and the degree of hydronephrosis is moderate or above the next; (5) Patients who are able to complete the study in accordance with the requirements of the trial protocol.

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant or preparing to become pregnant or breastfeeding; (2) Patients with severe cardiovascular, hepatobiliary (gallstones), kidney or other organ diseases; (3) Patients with malformation, stenosis, obstruction and postoperative scar adhesion at the nephroureteral junction or the ureter distal end of the stone; (4) Obstructive anuria, renal failure, chronic uremia, myeloid sponge kidney; (5) Patients with severe urinary tract infection, severe digestive system diseases (such as acute peptic ulcer, chronic ulcerative colitis, localized enteritis, intestinal obstruction); (6) Those with allergies or allergies to the known ingredients of this drug; (7) Use of drugs that can interfere with uric acid, affect stone formation, and have the effect of expelling stones 2 weeks before surgery; (8) Patients with abnormal coagulation function and anticoagulant drugs; (9) Patients with urinary tract tumors.

Design outcomes

Primary

MeasureTime frame
the weight of adherent stones on ureteral stent tube;

Secondary

MeasureTime frame
Pain VAS score improved at 4 weeks after the operation of upper urinary tract stones;Improvement in kidney function after the operation of upper urinary tract stones;Retention rate of ureteral stenting at 4 weeks after the operation of upper urinary tract stones;

Countries

China

Contacts

Public ContactLi Gang

Mianzhu People's Hospital

ligang88@aliyun.com+86 138 9020 6908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026